TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total conversion of oral arginine into NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kinetic profiles of plasma arginine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diameter of the superior mesenteric artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Doppler flow velocity in the superior mesenteric artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Change from Pre to Post Mindset Manipulation on Emotion Mindset Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Pre to Post Mindset Manipulation on Emotional Self-efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change on Self-Reported State Negative Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With a Post-bronchodilator FEV1/FVC <=70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygenation levels of blood in the feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Moderate and greater severity clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean intracellular drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of volunteers with at least 80% adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Correct Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery from anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ghrelin area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PYY area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brown adipose tissue activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Delirious Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to clinical relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech and swallowing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of customers achieving recommended blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulation Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature (Metaphase II) oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of HPV Type 6/11/16/18-related External Genital Warts, PIN, Penile, Perianal or Perineal Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Noisy breathing diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exhaled breath volatiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Global Impression Severity (CGIS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma reticulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall patient satisfaction with informed consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Menstrual Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the systemic Th1 immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the local immune response in peritumoral tissue (Th1/Th2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the local immune response in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression Free Survival rate at 9 months after randomisation
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change in modified Eczema Area and Severity Index (m-EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HAVG patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Mediterranean Diet Score (MDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain score after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound-QoL Global Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Off Periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent neutrophils bearing surface markers for IL-5 Receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of treatment for steroid-resistant aGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mortality of ESCC
Endpoint domain: Mortality/survival
Primary endpoint: incidence of ESCC
Endpoint domain: Mortality/survival
Primary endpoint: Absolute Change in Liver Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Adverse Events That Were Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Drug Events Geriatric Risk Score
Endpoint domain: Adverse events/effects
Primary endpoint: Vulvovaginal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Major Adverse Cardiac Events
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion of Induced Ventricular Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in probability of survival of all patients with SMA
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 13C02 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Cognitive Dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Neuropathy Score (TNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evoked nerve conduction velocity (NCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative Sensory Testing (QST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of time that intragastric pH is above 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in duration of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ulcers to heal within 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve signs of dry eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve symptoms of dry eyes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of complete responses (no vomiting and no rescue treatment)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of atrial fibrillation in patients with CIEDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of cardiac electrophysiology referrals from the E.D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of device and lead malfunctions in patients with CIEDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intrapulmonary drug concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual incidence rate of CKD
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analogue Pain Scale Averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilation depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPR pause times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunophenotyping of immune infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Positive End-Expiratory Pressure (PEEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetic profile of lesinurad
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic profile of lesinurad
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGA x BSA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCI accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of men with moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in AER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous abstinence rate (CAR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Clinical Attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of prolonged bleeding from dental procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for CPAP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rise in alpha-defensin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 12-Hour Lorazepam Requirement Pre- and Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-Hour Lorazepam Requirement Pre- and Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total and calculated free 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NSD 12 months postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time of glucose levels spent below 4.0 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of ATOD use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of lifetime sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value (NPV) of FDG PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of integrated myocardial revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of integrated myocardial revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Stopping Rule Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cranio-cervical flexor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of blue dye in the trachea and/or bronchi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ED50 dose response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation markers in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subjective response to IV cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the time-plasma concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Motor Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost-utility ratios
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PROM of the shared decision making process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delta Hemoglobin A1c Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in Thyroglobulin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative dose-intensity (RDI) of the myelosuppressive therapy course
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CR rate (complete response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of cryotherapy and LEEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intracranial Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving a Serotype-Specific Pneumococcal IgG Antibody Concentration >= 0.35 mcg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Local Reaction Within 5 Days After Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor Effect of AXL1717
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of cell counting and classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference between the analgesic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance Exercise Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance Exercise Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean log10 HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gag reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of pro-inflammatory and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution of complement C5a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution of CD 64 and CD 163 markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evolution of miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of PON1, HDL and LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Copper/Zinc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: York Measure of Quality of Behavioural Intensive Intervention (YMQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of thyroid nodules with volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in CAT-score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vibratory Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Apical Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limbal Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Edge Lift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Overall Confirmed Response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Progression at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Psychological measure of anxiety (VAS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-displaceable Tracer Binding Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with asexual falciparum parasitaemia on Day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with 'adequate clinical and parasitological response' (ACPR) before PCR-corrected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with 'early treatment failure' (ETF) before PCR-corrected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal epithelial abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cell-associated HIV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Post-operative Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in VO2Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain ATP production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any treatment-emergent serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of BOS172738
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Articulation of TREATED ITEMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Articulation of Untreated Items (Generalization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with biopsy confirmed intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fraction of metastatic nodes identified pre-surgically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF levels in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usual activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain/Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in length of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Raynaud Phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Raynaud Phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the Body Core Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Disseminated Tumor Cells (DTC) in Bone Marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Asthma control as measured by the ACQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ocular grittiness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface lissamine green staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PTSI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes